TD Cowen raises target to USD 190 for Twist Bioscience stock

Published on 10/18/2026 at 12:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen lifted its target to USD 190 on October 13, 2026. Twist Bioscience stock faces November 13, 2026 after USD 118.38 million third-quarter revenue.

Analyst target and upcoming test

TD Cowen lifted its Twist Bioscience target to USD 190 on October 13, 2026.
Fiscal third-quarter revenue reached USD 118.38 million, up 23.20 percent year over year.
Twist Bioscience had a USD 8.7 billion market capitalization as of October 16, 2026.
Nasdaq lists November 13, 2026 as the estimated next earnings date.

TWST, US90184D1000, Illustration mit AI erstellt.

Twist Bioscience (ISIN US90184D1000) became the subject of a sharper analyst target on October 13, 2026, when TD Cowen raised its price target from USD 115.00 to USD 190.00 and kept a Buy rating, as Markets Insider reported. The move puts execution against the next earnings report at the center of the investment case.

Revenue growth meets a higher bar

Twist reported USD 118.38 million of revenue for fiscal third quarter 2026, up 23.20 percent from the year-earlier period. The figure exceeded the USD 114.55 million consensus estimate, while adjusted earnings per share came in at a USD 0.56 loss against an expected USD 0.51 loss, according to MarketBeat. Revenue therefore beat expectations while the loss remained wider than analysts had forecast.

Three target changes shaped the story

On August 3, 2026, Twist reported fiscal third-quarter revenue of USD 118.38 million, as MarketBeat noted. On October 1, 2026, Guggenheim raised its target from USD 107.00 to USD 212.00 in a Buy-rated view, the same report said. On October 13, 2026, TD Cowen then lifted its target from USD 115.00 to USD 190.00, according to Markets Insider.

What tests the valuation next?

Twist had a market capitalization of USD 8.7 billion as of October 16, 2026. That valuation leaves the company needing to convert 23.20 percent fiscal third-quarter revenue growth into improving earnings, especially after the quarterly loss of USD 35.05 million. The company develops synthetic DNA and related products through a silicon-based platform, according to its Twist Bioscience investor-relations page.

Next reporting date

Nasdaq lists November 13, 2026 as the estimated next earnings date for Twist Bioscience, while noting that the date is algorithmically derived and may change, according to Nasdaq.

Company outlook

The upcoming report will show whether the company can sustain its fiscal 2026 growth profile while narrowing losses. The further course of trading is shown by the continuously updated real-time quote of Twist Bioscience stock.